FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283813085> ?p ?o ?g. }

• W4283813085 abstract "Article Figures and data Abstract Editor's evaluation Introduction Materials and methods Results Discussion Data availability References Decision letter Author response Article and author information Metrics Abstract Background: Lymphatic malformations (LMs) often pose treatment challenges due to a large size or a critical location that could lead to disfigurement, and there are no standardized treatment approaches for either refractory or unresectable cases. Methods: We examined the genomic landscape of a patient cohort of LMs (n = 30 cases) that underwent comprehensive genomic profiling using a large-panel next-generation sequencing assay. Immunohistochemical analyses were completed in parallel. Results: These LMs had low mutational burden with hotspot PIK3CA mutations (n = 20) and NRAS (n = 5) mutations being most frequent, and mutually exclusive. All LM cases with Kaposi sarcoma-like (kaposiform) histology had NRAS mutations. One index patient presented with subacute abdominal pain and was diagnosed with a large retroperitoneal LM harboring a somatic PIK3CA gain-of-function mutation (H1047R). The patient achieved a rapid and durable radiologic complete response, as defined in RECIST1.1, to the PI3Kα inhibitor alpelisib within the context of a personalized N-of-1 clinical trial (NCT03941782). In translational correlative studies, canonical PI3Kα pathway activation was confirmed by immunohistochemistry and human LM-derived lymphatic endothelial cells carrying an allele with an activating mutation at the same locus were sensitive to alpelisib treatment in vitro, which was demonstrated by a concentration-dependent drop in measurable impedance, an assessment of cell status. Conclusions: Our findings establish that LM patients with conventional or kaposiform histology have distinct, yet targetable, driver mutations. Funding: R.P. and W.A. are supported by awards from the Levy-Longenbaugh Fund. S.G. is supported by awards from the Hugs for Brady Foundation. This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center (CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science Foundation via Graduate Research Fellowship DGE-1143953. Clinical trial number: NCT03941782 Editor's evaluation The study examines the genomic landscape of a patient cohort of lymphatic malformations (LMs) through next-generation sequencing and immunocytochemistry. The authors identified actionable driver mutations in the P13KCA and NRAS genes. The study enhances our understanding of the genetic architecture of the otherwise disfiguring LMs in people. https://doi.org/10.7554/eLife.74510.sa0 Decision letter Reviews on Sciety eLife's review process Introduction Vascular anomalies, including lymphatic malformations (LMs), are usually diagnosed in children or young individuals and they can present as either isolated lesions or as part of somatic or congenital syndromes. Here, the term lymphatic malformation is used to include the clinicopathologic continuum of benign tumors of lymphatic origin (https://rarediseases.org/rare-diseases/lymphatic-malformations), including cystic lymphangioma, kaposiform lymphangiomatosis (KLM), and macro/microcystic LM. In general, LMs are managed by sclerotherapy, laser, or surgical interventions when there is an indication for therapy (Perkins et al., 2010). In certain cases, LMs can attain large sizes or involve critical locations, which poses treatment challenges such as the possibility of disfigurement. Genomic sequencing has demonstrated a somatic clonal origin for a number of nonmalignant growth conditions including LMs. Activating PIK3CA mutations have been reported in most pediatric patients with isolated or syndromic LMs (Luks et al., 2015). This finding has led to the use of mammalian target of rapamycin (mTOR) inhibitors for systemic therapy of unresectable LMs, given that mTOR is a molecule downstream of the PI3K pathway (Fruman et al., 2017). However, only a subset of patients responded, and the treatment can have substantial side effects. PI3K inhibitors have also been recently approved by the FDA for treatment of adults and children with severe manifestations PIK3CA-related Overgrowth Spectrum (termed PROS) who require systemic therapy, but the efficacy of alpelisib in isolated sporadic LMs is not at all clear. Activating NRAS mutations have been described in a subset of LM known as KLM (Barclay et al., 2019). KLM belong to a group of complex lymphatic anomalies that exhibit histologic and clinical features distinguishing them from classic LM. It is not as yet clear which oncogenic drivers, if any, are present in LMs with wild-type PIK3CA and NRAS alleles. To define the spectrum of genomic alterations and lesions present in LMs, here we have analyzed a patient cohort of LMs (n = 30 cases) assayed by clinical-grade genomic sequencing. Pathogenic activating mutations in PIK3CA and NRAS were the most common genetic alterations found. Strikingly, the PIK3CA and NRAS mutations were mutually exclusive with NRAS mutations being greatly enriched in LMs with kaposiform morphology. We have also performed an N-of-1 trial of the PI3Kα inhibitor alpelisib in a young man with an activating PIK3CA point mutation, presenting with a giant (unresectable) retroperitoneal and pancreatic LM, who had a dramatic and prolonged response to the drug lasting years, and we present confirmatory translational correlates in vitro. Materials and methods Genomics and DNA sequencing Request a detailed protocol Hybrid-capture DNA sequencing targeting exons of at least 324 cancer genes and select introns of 36 genes were performed on the patient samples; a subset (n = 2) were also analyzed with plus RNA sequencing of 265 genes to improve rearrangement detection. A total of 30 patient samples were sequenced with either the DNA-only assay (n = 28; Foundation One CDx, Foundation Medicine; Cambridge, MA) or the DNA + RNA assay (n = 2; Foundation One Heme, Foundation Medicine; Cambridge, MA). Immunohistochemistry Request a detailed protocol Immunohistochemistry (IHC) was performed on formalin-fixed, deparaffinized, 5-µm-thick sections mounted on charged slides. Antibodies to P-AKT (Ser473) and P-6S (Ser240/Ser244) were obtained from Cell Signaling Technology, Danvers, MA. Diaminobenzidine was used as the chromogen and hematoxylin as the counterstain. All stages of staining were carried out on an automated system (Ventana Discovery Research Instrument; Ventana, Tucson, Arizona). Positive and negative controls were appropriately reactive. A surgical pathologist with subspecialty interest in musculoskeletal pathology (T.J.B.) interpreted the results. Lymphatic malformation-lymphatic endothelial cell sensitivity to alpelisib in vitro Request a detailed protocol Lymphatic malformation-lymphatic endothelial cells (LM-LECs) were maintained as described (Boscolo et al., 2015) and negative for mycoplasma at the time of these studies. Mycoplasma test was performed using the MycoAlert Mycoplasma Detection Kit (Cat # LT07-218, Lonza) following the manufacturer’s instructions. Real-time analysis of cell viability was performed by using the xCELLigence system RTCA SP (ACEA Biosciences). Briefly, 5 × 103 LM-LECs per well were seeded in an E-Plate 96 (ACEA Biosciences) and cell proliferation was recorded hourly. When the cells reached the exponential growth phase, new media containing alpelisib at 1, 3, 10, 30, or 100 nM was added and alpelisib cytotoxic effect was recorded hourly. IC50 was calculated by using the dose–response curve function available in the xCELLigence software Version 2.0. Cell index (%) reflects cell viability. Clonogenic survival assays Request a detailed protocol For the clonogenic survival assay, the LM-LECs were trypsinized, counted, and plated in complete growth media on 6-well plates (Falcon) (400 cells/well). Seven days later, alpelisib (at the empirically determined IC50 from a standard calibration curve) was added in duplicate wells. After 24 or 48 hr of incubation, cells were fixed and stained in 50% methanol in water containing 0.3% crystal violet to facilitate counting of colonies (≥50cells). Statistics All values are expressed as mean with error bars expressed as standard deviation. For comparison between untreated (negative), dimethyl sulfoxide control, and alpelisib-treated LM-LEC cells, the ordinary one-way analysis of variance and Tukey’s multiple comparisons test with a single pooled variance were used. Statistical analysis was performed using the GraphPad Prism 7.0d software (GraphPad Software Inc, San Diego, CA). Fisher’s exact test was used for categorical data, owing to the sizes of the cohorts. A two-tailed p value of <0.05 was considered to be statistically significant. Study approval Request a detailed protocol Approval for this study, including a waiver of informed consent and Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the Western Institutional Review Board (IRB; protocol #20152817). A single-institution personalized clinical protocol to treat the patient with the experimental PI3Kα inhibitor alpelisib was scientifically reviewed by the Protocol Review and Monitoring Committee (PRMC) and approved by the local Institutional Review Board (IRB) of the University of New Mexico Comprehensive Cancer Center. The study (NCT03941782) was conducted in accordance with the protocol, Good Clinical Practice guidelines, and the provisions of the Declaration of Helsinki. CARE reporting guidelines were also used for this patient (Gagnier et al., 2013). The index patient signed an informed written consent form. Results Mutational landscape and histopathology of LMs A set of 30 cases of LMs (from 30 individual patients) were assayed with genomic profiling at Foundation Medicine, Inc (Cambridge, MA). Twenty-eight cases were sequenced using hybrid-capture next-generation sequencing (NGS) targeting exons of 300 + cancer genes and select introns of 36 genes. Two other cases were sequenced using hybrid-capture based DNA sequencing targeting exons of 406 + cancer genes and select introns of 36 genes, plus RNA sequencing of 265 genes for rearrangement calling. The patients were predominantly pediatric age (median 9-year-old; range, 1- to 45-year-old), with a slight female predominance (17 females, 57%–13 males, 43%). Seven patients had a documented history of prior treatment with an mTOR inhibitor, such as sirolimus. Seven patients (23%) had documentation of clinical diagnoses of overgrowth syndromes including Congenital Lipomatous Overgrowth with Vascular, Epidermal, and Skeletal anomalies (termed CLOVES), Klippel–Trenaunay syndrome, and phosphatase and tensin homolog (PTEN)-like hamartoma syndrome at the time of testing. Twelve patients (40%) had multifocal disease and eight patients had involvement of bone and visceral sites (Table 1). Expert histopathological review showed that only four (13%) had kaposiform morphology, while 26 (87%) had conventional histology. The estimated histopathologic purity ranged from 10% to 70% (median 20%). Table 1 Clinical and histological features of lymphatic malformation cohort. PatientAge(years)SexSubmitted clinical syndromeLocalized vs. multifocalLocation of LM(s)Specimen typeLM histologyPIK3CA or NRAS alteration% VAF19MCLOVESMultifocalSuperficial soft tissuesExcisionConventionalPIK3CA E542K1424F LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA E542K731F LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA H1047R11417M LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA H1047R4518M LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA H1047L468FKlippel–TrenaunayLocalizedSuperficial soft tissuesExcisionConventionalPIK3CA H1047R979M LocalizedVisceralCore biopsyConventionalPIK3CA E545K783F LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA C420R5923M LocalizedVisceralIncisional biopsyConventionalPIK3CA H1047R41016FPTEN-like hamartomaLocalizedSuperficial soft tissuesExcisionConventionalPIK3CA H1047R3113FCLOVESMultifocalSuperficial soft tissuesExcisionConventionalPIK3CA E545K12121M MultifocalSuperficial soft tissuesExcisionConventionalPIK3CA H1047R2134F LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA E542K6145M LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA H1047R5151F LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA E545K11614F MultifocalVisceralExcisionConventionalPIK3CA C420R14172FCLOVESMultifocalSuperficial soft tissuesExcisionConventionalPIK3CA C420R381816FCLOVESLocalizedSuperficial soft tissuesExcisionConventionalPIK3CA E453K321910FCLOVESMultifocalSuperficial soft tissuesExcisionConventionalPIK3CA H1047L15209M LocalizedSuperficial soft tissuesExcisionConventionalPIK3CA H1047R5219F MultifocalVisceralExcisionKaposiformNRAS Q61R5228M MultifocalSuperficial soft tissuesExcisionKaposiformNRAS Q61R5239F MultifocalVisceralExcisionKaposiformNRAS Q61R12445M MultifocalVisceralCore biopsyConventionalNRAS Q61R62510F LocalizedSuperficial soft tissuesCore biopsyKaposiformNRAS Q61R142617M MultifocalSuperficial soft tissuesExcisionConventionalWTNA2724M LocalizedBoneCore biopsyConventionalWTNA283M MultifocalSuperficial soft tissuesExcisionConventionalWTNA2911F LocalizedSuperficial soft tissuesExcisionConventionalWTNA309F LocalizedSuperficial soft tissues, boneBiopsyConventionalWTNA CLOVES – congenital lipomatous overgrowth, vascular anomalies, epidermal nevi, and skeletal anomalies; NA – not applicable; VAF – variant allele frequency of PIK3CA or NRAS. Mutational profiling showed that these LMs had uniformly low tumor mutational burden (median, zero mutations/Mb; range, 0–2.6 mutations/Mb), and none had evidence of microsatellite instability. The most common mutations were activating mutations in PIK3CA, seen in 20 (67%), and activating NRAS mutations, seen in 5 (17%) (Figure 1A, B). The PIK3CA mutations included hotspot mutations in both the helical domain and the kinase domain (Samuels et al., 2004). The NRAS mutations all altered the known hotspot at residue glutamine 61 (Q61) in the phosphorylation binding loop. Of the five patients (17%) with no alterations in PIK3CA and NRAS, one case (Patient #29; Table 1) had an activating GOPC–ROS1 fusion (Figure 1C) with a ROS1 missense point mutation. Similar GOPC–ROS1 fusions have been reported in pediatric gliomas in the setting of microdeletion of chromosome 6q228, and have also been found in adult lung cancer (Drilon et al., 2021). Figure 1 Download asset Open asset Mutational landscape and histopathology of lymphatic malformations (LMs). (A) Oncoprint showing mutational landscape of 30 LM samples sequenced. (B) Lollipop plot showing spectrum of PIK3CA and NRAS mutations in this cohort. (C) Schema showing details of GOPC–ROS1 fusion identified in an NRAS and PIK3CA wild-type LM. (D) Representative histologic images for LMs with conventional and kaposiform histology. The relative frequencies of PIK3CA and NRAS mutations in the two histologic variants are plotted. The variant allele frequencies (VAFs) of the PIK3CA and NRAS mutations were relatively low (median, 6%; range, 1–38%), compatible with relatively low histopathologic estimated percentage of tumor nuclei (%TN) to overall cellular nuclei (median, 20%; range, 10–70%). These results suggest that the PIK3CA and NRAS mutations were likely clonal, but in the setting of relatively low tumor purity in the specimens. Enrichment of NRAS mutations in LMs with kaposiform features Histopathological analysis of the lesions by an board-certified dermatopathologist (J.Y.T.) identified that four (13%) of the analyzed specimens had kaposiform histopathological features with highly cellular, clustered, or sheet-like, proliferation of spindled lymphatic cells admixed with dilated thin-walled lymphatic vessels (Figure 1D). The remaining 26 lesions (87%) had conventional histopathological features of classic LM, with proliferation of dilated, thin-walled lymphatic vessels with or without luminal proteinaceous material. Lymphatic phenotype of the cells was confirmed by immunopositivity for PROX1 or D2-40, by report. Of the conventional histology LM cases (n = 26), 20 (77%) had a PIK3CA mutation, while 1 (4%) had a NRAS mutation, and 5 (19%) were wild-type for both genes, including a single case with a GOPC–ROS1 genetic fusion. Notably, all four cases of LM with kaposiform features had an activating NRAS mutation, consistent with enrichment of NRAS mutation (p = 0.00018) and lack of PIK3CA mutation in this histology (p = 0.0046). The lone NRAS-mutant LM with conventional histology was a small core needle-biopsy specimen of a large visceral tumor, raising the possibility that the histopathologic features of the sampled tissue may not have been representative of the entire lesion due to the histologic spatial heterogeneity often seen in LMs with kaposiform histology. Additional histopathologic features were assessed, including altered adipose tissue, muscularized blood vessels, vascular endothelial cell atypia, and inflammation; no statistical significance was identified between the four NRAS-mutant LM cases and the remainder of the patient cohort. Case report and N-of-1 clinical trial results One of the conventional histology LMs was a 23-year-old male with no significant medical or family history who presented with subacute abdominal pain (Patient #9, Table 1). He was hospitalized and his exam revealed a distended abdomen that was tender to palpation. A computed tomography exam revealed a large solid mass based on the retroperitoneal area and the pancreas (Figure 2A), and a neoplastic process was suspected. A core needle biopsy was attempted but yielded no definitive tissue diagnosis. An open laparoscopic surgical biopsy was performed and revealed a vascular tumor with features of a giant retroperitoneal and pancreatic LM (Figure 2D, E). After discussing a surgical approach, the patient and the surgical team decided not to proceed due to the complexity of surgical resection and associated risks. The tissue was submitted for NGS to identify potential biomarkers for targeted therapy. Figure 2 Download asset Open asset Imaging and histological analysis of lymphatic malformation (LM) patient. (A) Baseline CT abdomen scan at the time of presentation demonstrating a large retroperitoneal/pancreatic LM. (B) CT abdomen scan 6 weeks after the initiation of alpelisib. (C) CT abdomen scan 1 year into the trial. (D, E) Hematoxylin and eosin (H&E)-stained photomicrographs of the LM showing dilated lymphatic channels percolating through visceral fat and associated patchy lymphocytic inflammation (×4 and ×20, respectively). (F) Immunohistochemistry utilizing an anti-P-6S antibody demonstrates PI3Ka pathway activation within the channels’ lining cells. (G) Anti-P-AKT positivity in the lining endothelium of lymphatic channels as well. Clinical-grade sequencing of the biopsy sample from Patient #9 uncovered a single activating point mutation in PIK3CA (H1047R). All other genes in the panel were wild-type except for another unit of the PI3K complex (PIK3C2B) that showed a variant (R458Q) of unknown significance (VUS). To confirm activation of the PI3Kα pathway, we performed IHC staining of the downstream targets (P-AKT and P-6S), and, as predicted, these phosphorylation events were detected in the lining cells of the abnormal lymphatic channels (Figure 2F, G). Based on the genomic profile, we designed and offered this young man a single-patient (N-of-1) personalized clinical trial of the PI3Kα inhibitor alpelisib (NCT03941782), which at the time was still investigational (non-FDA approved). Screening procedures included an echocardiogram that revealed an ejection fraction (EF) of 47%. A cardiac MRI confirmed a low EF with no infiltrative process or other abnormalities. Paradoxically, the patient was completely asymptomatic from a cardiac standpoint and he was able to run two miles on a daily basis. We hypothesized that the decreased EF, in the absence of accompanying clinical signs or symptoms of heart failure, was likely artefactual due to hemodynamic changes related to the very large circulatory volume sequestration in his abdomen. The patient was started on alpelisib daily dose of 350 mg orally (Juric et al., 2018) and he reported regression of his abdominal bulge within a few days. He reported no adverse events and was closely monitored for hyperglycemia. Repeated echocardiogram 2 months later showed normalization of the EF. A CT scan of the abdomen done 6 weeks into the trial revealed remarkable shrinkage of the LM (Figure 2B). Follow-up CT scans showed progressive reduction until complete response at 1 year of trial initiation (Figure 2C). The patient continued to do well on maintenance alpelisib for 2 years with no evidence of progression. After 2 years, alpelisib was discontinued due to theoretical concerns about long-term adverse impact on vascular homeostasis. Unfortunately, the mass recurred after a few weeks so the patient was resumed on alpelisib with a second deep partial response, which is still ongoing for over 3 years. Alpelisib inhibits primary PI3Kα-mutant LM-derived endothelial cells We have also investigated the concentration-dependent effects of alpelisib on LM-LECs isolated from a surgically resected specimen (Boscolo et al., 2015). Targeted sequencing of DNA from LM-LECs identified a somatic missense mutation in PIK3CA (H1047L), the same locus altered in our alpelisib-treated patient and the site of half of the PIK3CA alterations in the LM cohort studied (Table 1). In addition, a nonsense mutation of the regulatory PI3K unit PIK3R3 (R309*) was also detected in the CD31-positive LM-LECs and CD31-negative nonendothelial cells isolated from the same LM, indicating its germline origin (Boscolo et al., 2015). We investigated the effect of alpelisib on the growth of LM-LECs and a concentration-dependent response curve was observed (Figure 3). The IC50 of alpelisib against LM-LECs was empirically determined in vitro to be 4.72 × 10−9 M at 24 hr. This in vitro translational model confirms the sensitivity of LM-derived human cells containing a target H1047R/L mutation to alpelisib. Figure 3 Download asset Open asset Alpelisib reduces lymphatic malformation-lymphatic endothelial cell (LM-LEC) viability. (A) Logarithmic dose–response curve of alpelisib was performed using the xCELLigence RTCA system. 1, 3, 10, 30, and 100 nM (n = 5 replicates) of alpelisib were used to determine the concentration–response curve. The alpelisib half maximal inhibitory concentration (IC50) was calculated for LM-LEC at 24 hr after treatment as 4.72 × 10−9 M. Error bars are shown as mean +/- standard deviation (SD), which was automatically calculated for each data point by the xCELLigence RTCA system software (Version 2.0) based on five replicates per drug concentration. (B) Illustrative picture of LM-LEC clonogenic plaques at 24 hr after alpelisib treatment (4.72 × 10−9 M). Negative, no treatment; dimethyl sulfoxide (DMSO), vehicle control. Experiments were performed two times with similar results. LM-LEC colonies were stained with crystal violet (0.3%). (C) Colony count 24 hr after alpelisib treatment (4.72 × 10−9 M; n = 2 wells/condition). Error bars are shown as mean +/- SD calculated by GraphPad Prism by determining the square root of variance for each data point deviation relative to the mean. Refined genomic and sequencing analyses We performed whole-genome sequencing (WGS) on paired LM/germline DNA from our index patient to explore the mutational profile beyond the genes that were probed in the Clinical Laboratory Improvement Amendments (CLIA)-approved clinical sequencing assay. The PIK3CA H1047R mutation was identified with a VAF of 11%. This finding is consistent with the ≤10% rate of mutant cells, and low tumor cellularity of LMs with PIK3CA mutation (Luks et al., 2015). Few other somatic coding mutations were identified in the LM tissue (Supplementary file 1). To gain further molecular mechanistic insight, we have also performed RNA-seq studies to identify gene expression patterns within the LM sample from our index patient compared to normal tissue (Figure 4). RNA-seq data of biopsy samples from Patient #9 (n = 2 samples; Figure 4A, Group A) were compared to several normal human control tissue samples from bladder, colon, kidney, and salivary gland (n = 4, one sample per each tissue; Figure 4A, Group B). There is little difference between the two LM samples, but, by using an arbitrary cutoff of at least twofold up or down with adjusted p values of 0.05 or less, we identified 668 upregulated and 850 downregulated genes. The heatmap summarizes the results of the differential gene expression analysis; 125 genes are shown. The volcano plot summarizes the distribution of genes that were differentially expressed (Figure 4B). Here, the vertical axis shows the p value and the horizontal axis shows the fold-change. The genes that were more than twofold changed and had an adjusted p value less than 0.05 are shaded red. Similar numbers of genes were up- and downregulated. Several of the most highly induced genes, CHI3L1, GPX1, PLIN1, PLIN4, and JAK3, have been linked to enhanced growth or cell survival in other tumor types (Cheng et al., 2019; Qiu et al., 2018; Sirois et al., 2019; Vadivel et al., 2021; Zhang et al., 2020). Finally, a preliminary Gene Ontogeny (GO) analysis (Subramanian et al., 2007) of Patient #9 LM revealed enrichment of mRNA of genes involved in vascular development, cell motility, inflammatory response, positive regulation of response to stimuli, blood vessel morphogenesis, among others; notably, the kinase JAK3 gene was one of the highest expression mRNAs in the LMs compared to normal tissue controls. Figure 4 Download asset Open asset RNA-seq analysis of lymphatic malformation (LM) samples from index patient (#9). (A) The heatmap summarizes the results of the differential gene expression analysis. Up- and downregulated genes are shaded red and blue, respectively. (B) The volcano plot summarizes the distribution of genes that were differentially expressed. The vertical axis shows the p value and the horizontal shows the fold-change. The genes that were more than twofold changed and had an adjusted p value less than 0.05 are shaded red. Similar numbers of genes were up- or downregulated. Discussion Here, we report the mutational landscape of a patient cohort of LMs (n = 30 cases) which underwent comprehensive genomic profiling. We have confirmed prior reports that hotspot activating mutations in PIK3CA are common driver events in these lesions, seen in 20 (67%) of these cases. Interestingly, NRAS mutations were seen in an additional five (17%) cases and were particularly enriched in LMs with a kaposiform histopathology. This finding supports previous studies that have shown that LMs with kaposiform features likely represent a distinct entity (KLA) (Barclay et al., 2019; Croteau et al., 2014). KLM have distinct clinical, histologic, and genomic features. Clinically, they are more likely to occur in young patients and commonly present as generalized processes with involvement of the mediastinum, pleura, and pericardium. Histologically, they are composed of highly cellular sheet-like and nodular proliferations of spindle cells, reminiscent of Kaposi sarcoma (Croteau et al., 2014). Unlike Kaposi sarcoma, the tumor cells lack immunopositivity for human herpesvirus-8 (HHV-8) latency-associated nuclear antigen (LANA). Genomically, recent studies have shown they tend to harbor somatic activating alterations in NRAS (Barclay et al., 2019Barclay et al., 2019). As a caveat, for the one NRAS-mutant LM with classic histology, the histologic classification was based on a small biopsy, and it is certainly possible that kaposiform histology was present in the large visceral LM but not captured by the limited sampling by core needle biopsy. Importantly, three of the five patients (60%) with NRAS-mutant LMs had failed treatment with sirolimus prior to NGS. There are reports that some NRAS-mutant LMs may respond to treatment with MEK inhibitors (Dummer et al., 2017), suggesting this may be an option for LMs with kaposiform features. Of the five cases without either PIK3CA or NRAS mutations, all of classic histology, a single case had a known pathogenic in-frame GOPC–ROS1 genetic fusion predicted to have an intact ROS1 kinase domain and thus potentially function as the driver. Similar GOPC–ROS1 fusions have been seen in pediatric gliomas and adult lung cancers and may be sensitive to ROS1 inhibitors (Davare et al., 2018; Drilon et al., 2021). These data suggest that most LMs may have a potentially actionable driver mutation, with PIK3CA mutations dominating LMs with conventional histology and NRAS mutations predominantly or exclusively seen in the minor subset of LMs with kaposiform features. It is possible that the other NRAS and KRAS wild-type LMs may also have oncogenic alterations in other members of the PIK3CA or MAPK signaling pathway members that were not profiled by targeted sequencing strategies. We appreciate that one limitation of our study is that the cohort presented in Table 1 was established from clinical information provided by the ordering physicians early in the course of diagnostic investigation. Therefore, we cannot rule out that the working clinical diagnosis and/or pathologic diagnoses were refined after genomic analyses without transmissi" @default.
• W4283813085 created "2022-07-06" @default.
• W4283813085 creator A5001304346 @default.
• W4283813085 creator A5004116236 @default.
• W4283813085 creator A5007869493 @default.
• W4283813085 creator A5007974064 @default.
• W4283813085 creator A5015007048 @default.
• W4283813085 creator A5016120310 @default.
• W4283813085 creator A5016546470 @default.
• W4283813085 creator A5036781090 @default.
• W4283813085 creator A5042976999 @default.
• W4283813085 creator A5043723479 @default.
• W4283813085 creator A5056381387 @default.
• W4283813085 creator A5061989008 @default.
• W4283813085 creator A5066532151 @default.
• W4283813085 creator A5067701996 @default.
• W4283813085 creator A5081124060 @default.
• W4283813085 creator A5082131768 @default.
• W4283813085 creator A5083643114 @default.
• W4283813085 creator A5084480627 @default.
• W4283813085 creator A5089021632 @default.
• W4283813085 date "2022-06-13" @default.
• W4283813085 modified "2023-10-18" @default.
• W4283813085 title "Author response: Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial" @default.
• W4283813085 doi "https://doi.org/10.7554/elife.74510.sa2" @default.
• W4283813085 hasPublicationYear "2022" @default.
• W4283813085 type Work @default.
• W4283813085 citedByCount "0" @default.
• W4283813085 crossrefType "peer-review" @default.
• W4283813085 hasAuthorship W4283813085A5001304346 @default.
• W4283813085 hasAuthorship W4283813085A5004116236 @default.
• W4283813085 hasAuthorship W4283813085A5007869493 @default.
• W4283813085 hasAuthorship W4283813085A5007974064 @default.
• W4283813085 hasAuthorship W4283813085A5015007048 @default.
• W4283813085 hasAuthorship W4283813085A5016120310 @default.
• W4283813085 hasAuthorship W4283813085A5016546470 @default.
• W4283813085 hasAuthorship W4283813085A5036781090 @default.
• W4283813085 hasAuthorship W4283813085A5042976999 @default.
• W4283813085 hasAuthorship W4283813085A5043723479 @default.
• W4283813085 hasAuthorship W4283813085A5056381387 @default.
• W4283813085 hasAuthorship W4283813085A5061989008 @default.
• W4283813085 hasAuthorship W4283813085A5066532151 @default.
• W4283813085 hasAuthorship W4283813085A5067701996 @default.
• W4283813085 hasAuthorship W4283813085A5081124060 @default.
• W4283813085 hasAuthorship W4283813085A5082131768 @default.
• W4283813085 hasAuthorship W4283813085A5083643114 @default.
• W4283813085 hasAuthorship W4283813085A5084480627 @default.
• W4283813085 hasAuthorship W4283813085A5089021632 @default.
• W4283813085 hasBestOaLocation W42838130851 @default.
• W4283813085 hasConcept C126322002 @default.
• W4283813085 hasConcept C143724316 @default.
• W4283813085 hasConcept C143998085 @default.
• W4283813085 hasConcept C151730666 @default.
• W4283813085 hasConcept C2776694085 @default.
• W4283813085 hasConcept C3019096185 @default.
• W4283813085 hasConcept C71924100 @default.
• W4283813085 hasConcept C86803240 @default.
• W4283813085 hasConceptScore W4283813085C126322002 @default.
• W4283813085 hasConceptScore W4283813085C143724316 @default.
• W4283813085 hasConceptScore W4283813085C143998085 @default.
• W4283813085 hasConceptScore W4283813085C151730666 @default.
• W4283813085 hasConceptScore W4283813085C2776694085 @default.
• W4283813085 hasConceptScore W4283813085C3019096185 @default.
• W4283813085 hasConceptScore W4283813085C71924100 @default.
• W4283813085 hasConceptScore W4283813085C86803240 @default.
• W4283813085 hasLocation W42838130851 @default.
• W4283813085 hasOpenAccess W4283813085 @default.
• W4283813085 hasPrimaryLocation W42838130851 @default.
• W4283813085 hasRelatedWork W2039151778 @default.
• W4283813085 hasRelatedWork W2067315169 @default.
• W4283813085 hasRelatedWork W2314160335 @default.
• W4283813085 hasRelatedWork W2746237839 @default.
• W4283813085 hasRelatedWork W2766558764 @default.
• W4283813085 hasRelatedWork W2898602143 @default.
• W4283813085 hasRelatedWork W3090963952 @default.
• W4283813085 hasRelatedWork W4366141150 @default.
• W4283813085 hasRelatedWork W4366142228 @default.
• W4283813085 hasRelatedWork W4366142243 @default.
• W4283813085 isParatext "false" @default.
• W4283813085 isRetracted "false" @default.
• W4283813085 workType "peer-review" @default.